Loading...

James Marks, MD, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentAnesthesia
Address1001 Potrero Ave
San Francisco CA 94110
Phone415-206-3256
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1979 School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    Antibody Research Technology Center
    NIH/NCI P41CA196276Sep 24, 2014 - Aug 31, 2019
    Role: Principal Investigator
    Generation of therapeutic antibodies to serotype F botulism
    NIH/NIAID R01AI104579Feb 1, 2013 - Jan 31, 2018
    Role: Principal Investigator
    Trispecific monoclonal antibody for botulinum neurotoxin intoxication therapy
    NIH/NIAID R33AI101539Jun 20, 2012 - May 31, 2017
    Role: Principal Investigator
    Trispecific monoclonal antibody for botulinum neurotoxin intoxication therapy
    NIH/NIAID R21AI101539Jun 1, 2012 - May 31, 2014
    Role: Principal Investigator
    Development of botulinum neurotoxin immunotherapy, serotypes C, D, F, and G
    NIH/NIAID U01AI075443Aug 15, 2007 - Jul 31, 2013
    Role: Principal Investigator
    Pacific Southwest RCE for Biodefense &Emerging Infectious Diseases Research
    NIH U54AI065359May 20, 2005 - Apr 30, 2014
    Role: Co-Investigator
    Development of botulinum neurotoxin immunotherapy
    NIH/NIAID U01AI056493Jul 15, 2003 - Dec 31, 2008
    Role: Principal Investigator
    Deciphering toxin neutralization by oligoclonal antibody
    NIH/NIAID R21AI053389Sep 1, 2002 - Aug 31, 2005
    Role: Principal Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH/NCI U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Co-Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks J. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS One. 2017; 12(3):e0174187. PMID: 28323873.
      View in: PubMed
    2. Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks J, Drummond DC, Lugovskoy AA. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2016 Nov 17; 0. PMID: 27854147.
      View in: PubMed
    3. Peyton C, Yang E, Msall ME, Adde L, Støen R, Fjørtoft T, Bos AF, Einspieler C, Zhou Y, Schreiber MD, Marks J, Drobyshevsky A. White Matter Injury and General Movements in High-Risk Preterm Infants. AJNR Am J Neuroradiol. 2016 Oct 27. PMID: 27789448.
      View in: PubMed
    4. Fan Y, Barash JR, Lou J, Conrad F, Marks J, Arnon SS. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis. 2016 May 15; 213(10):1606-14. PMID: 26936913.
      View in: PubMed
    5. Krombach JW, Marks J, Dubowitz G, Radke OC. Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety. Anesth Analg. 2015 Oct; 121(4):1097-103. PMID: 26378706.
      View in: PubMed
    6. Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks J, Pèlegrin A, Poul MA. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Mol Cancer Ther. 2015 Nov; 14(11):2595-605. PMID: 26358753.
      View in: PubMed
    7. Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks J. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel). 2015 Sep; 7(9):3405-23. PMID: 26343720; PMCID: PMC4591640.
    8. Krombach JW, Edwards WA, Marks J, Radke OC. Checklists and Other Cognitive Aids For Emergency And Routine Anesthesia Care-A Survey on the Perception of Anesthesia Providers From a Large Academic US Institution. Anesth Pain Med. 2015 Aug; 5(4):e26300. PMID: 26568921.
      View in: PubMed
    9. Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks J, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia. 2016 Mar; 30(3):692-700. PMID: 26286117.
      View in: PubMed
    10. Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks J. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One. 2015; 10(8):e0135306. PMID: 26275214; PMCID: PMC4537209.
    11. Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks J, Baron JL, Krummel MF, Nishimura SL. TGF-ß-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. J Immunol. 2015 Aug 1; 195(3):1182-90. PMID: 26109638; PMCID: PMC4506848 [Available on 08/01/16].
    12. Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks J, Mallick P, Reiter RE, Wu AM. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct; 28(10):307-16. PMID: 25991864; PMCID: PMC4607741 [Available on 10/01/16].
    13. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks J, Baron JL, Nishimura SL. Transforming Growth Factor-ß and Interleukin-1ß Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 5; 290(23):14717-28. PMID: 25918170; PMCID: PMC4505537 [Available on 06/05/16].
    14. D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks J, Litwin S, Robinson MK. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One. 2014; 9(11):e112376. PMID: 25386657; PMCID: PMC4227695.
    15. Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks J, Zhou Y. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One. 2014; 9(10):e111339. PMID: 25353955; PMCID: PMC4213037.
    16. Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks J, Wu AM. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. PMID: 25143449; PMCID: PMC4221648.
    17. Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks J, Varnum SM. Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Analyst. 2014 Oct 21; 139(20):5093-102. PMID: 25112421.
      View in: PubMed
    18. Tavaré R, Wu WH, Zettlitz KA, Salazar FB, McCabe KE, Marks J, Wu AM. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation. Protein Eng Des Sel. 2014 Oct; 27(10):317-24. PMID: 25095796; PMCID: PMC4191443.
    19. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks J, Baron JL, Nishimura SL. Selective targeting of TGF-ß activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014 Jun 18; 6(241):241ra79. PMID: 24944194; PMCID: PMC4341974.
    20. Jones AR, Stutz CC, Zhou Y, Marks J, Shusta EV. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May; 9(5):664-74. PMID: 24644233; PMCID: PMC4073886.
    21. Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks J, Binz T, Rummel A. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014 Apr 2; 588(7):1087-93. PMID: 24583011; PMCID: PMC4067265.
    22. Janardhanan P, Mello CM, Singh BR, Lou J, Marks J, Cai S. RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta. 2013 Dec 15; 117:273-80. PMID: 24209341; PMCID: PMC3909959.
    23. Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks J, Rummel A, Binz T. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013 Jul 1; 453(1):37-47. PMID: 23621114.
      View in: PubMed
    24. Jones RG, Marks J. Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol. 2013 Jun; 62(Pt 6):828-35. PMID: 23518650.
      View in: PubMed
    25. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks J, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906. PMID: 23024593; PMCID: PMC3447386.
    26. Zhang Y, Lou J, Jenko KL, Marks J, Varnum SM. Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem. 2012 Nov 15; 430(2):185-92. PMID: 22935296; PMCID: PMC3589981.
    27. Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks J. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012 Nov 15; 430(2):141-50. PMID: 22922799; PMCID: PMC4209713.
    28. Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks J, Chokhawala H, Clark DS, Francis MB. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28; 6(8):6675-80. PMID: 22830952; PMCID: PMC3435507.
    29. McCabe KE, Liu B, Marks J, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47. PMID: 21630083; PMCID: PMC3227780.
    30. Zhou Y, Zhao L, Marks J. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15; 526(2):107-13. PMID: 22627065; PMCID: PMC4209712.
    31. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks J. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76. PMID: 22564724; PMCID: PMC4209485.
    32. Liu YY, Rigsby P, Sesardic D, Marks J, Jones RG. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem. 2012 Jun 1; 425(1):28-35. PMID: 22406430.
      View in: PubMed
    33. Zhou Y, Marks J. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012; 502:43-66. PMID: 22208981; PMCID: PMC4180867.
    34. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks J, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012; 502:139-66. PMID: 22208985.
      View in: PubMed
    35. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks J, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan; 11(1):143-53. PMID: 22090420.
      View in: PubMed
    36. Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks J, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011; 12:58. PMID: 22085466; PMCID: PMC3250939.
    37. Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks J, Foung SK. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011 Dec 23; 286(51):44218-33. PMID: 22002064; PMCID: PMC3243554.
    38. Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks J. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15; 421(2):351-61. PMID: 22037290; PMCID: PMC4209596.
    39. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks J, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin avß8-mediated activation of TGF-ß. J Clin Invest. 2011 Jul; 121(7):2863-75. PMID: 21646718; PMCID: PMC3223836.
    40. Gray SA, Barr JR, Kalb SR, Marks J, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ. Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng. 2011 Oct; 108(10):2456-67. PMID: 21538339; PMCID: PMC3203252.
    41. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks J, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011 Mar 15; 71(6):2250-9. PMID: 21406401; PMCID: PMC3077882.
    42. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks J, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011 Mar 15; 17(6):1509-20. PMID: 21177408; PMCID: PMC3060271.
    43. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks J. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel. 2011 Mar; 24(3):321-31. PMID: 21149386; PMCID: PMC3038462.
    44. Zhou Y, Zou H, Zhang S, Marks J. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol. 2010 Nov 19; 404(1):88-99. PMID: 20851130; PMCID: PMC4195448.
    45. Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks J, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One. 2010; 5(8):e12237. PMID: 20808925; PMCID: PMC2923190.
    46. Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks J, Goldblatt M, Kinch M. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010; 2(4):368-80. PMID: 20733947; PMCID: PMC2923861.
    47. Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks J, Poul MA. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010 Jul 1; 70(13):5497-506. PMID: 20530676.
      View in: PubMed
    48. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks J, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8):1529-38. PMID: 20354850; PMCID: PMC2903645.
    49. Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks J. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010 Apr; 23(4):311-9. PMID: 20156888; PMCID: PMC2841544.
    50. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks J, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15; 70(4):1505-12. PMID: 20145119; PMCID: PMC2823079.
    51. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks J. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010 Apr 9; 397(4):1106-18. PMID: 20138889; PMCID: PMC2903050.
    52. Cao Y, Marks JD, Marks J, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res. 2009 Dec 1; 69(23):8987-95. PMID: 19934334.
      View in: PubMed
    53. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks J, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 4; 141(1):13-21. PMID: 19686789.
      View in: PubMed
    54. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks J. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009 Oct; 77(10):4305-13. PMID: 19651864; PMCID: PMC2747958.
    55. Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks J, Lou J, Grate JW. Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem. 2009 Jul 15; 81(14):5783-93. PMID: 19530657.
      View in: PubMed
    56. Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks J, Bruckner-Lea CJ. Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron. 2009 Sep 15; 25(1):179-84. PMID: 19643593; PMCID: PMC2728038.
    57. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks J, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One. 2009; 4(4):e5355. PMID: 19399171; PMCID: PMC2670495.
    58. Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks J, Bruckner-Lea CJ. Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Analyst. 2009 May; 134(5):987-96. PMID: 19381395.
      View in: PubMed
    59. Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks J, Liu B. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May; 87(5):507-14. PMID: 19219419; PMCID: PMC2796542.
    60. Noble CO, Guo Z, Hayes ME, Marks J, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol. 2009 Sep; 64(4):741-51. PMID: 19184019; PMCID: PMC2717390.
    61. Zhou Y, Marks J. Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol. 2009; 525:145-60, xv. PMID: 19252832.
      View in: PubMed
    62. Dimitrov DS, Marks J. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol. 2009; 525:1-27, xiii. PMID: 19252861; PMCID: PMC3402212.
    63. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks J, Braun J, Gordon LK, Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res. 2008 Nov 15; 14(22):7367-77. PMID: 19010852; PMCID: PMC3109074.
    64. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks J, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 4; 99(9):1415-25. PMID: 18841159; PMCID: PMC2576487.
    65. Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks J, Pang SF, Kan YW. Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology. 2008; 51(3):173-81. PMID: 18724064.
      View in: PubMed
    66. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks J, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1; 14(3):875-82. PMID: 18245551; PMCID: PMC2643368.
    67. Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks J, Xie G, Brettin TS. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One. 2007; 2(12):e1271. PMID: 18060065; PMCID: PMC2092393.
    68. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks J, Nakagawa T, Montal M. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem. 2008 Feb 15; 283(7):3997-4003. PMID: 18032388.
      View in: PubMed
    69. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks J, Liu B. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007 Oct; 6(10):2737-46. PMID: 17938267.
      View in: PubMed
    70. Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks J, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007 Oct; 30(7):684-93. PMID: 17893561.
      View in: PubMed
    71. Hasegawa K, Hu C, Nakamura T, Marks J, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol. 2007 Dec; 81(23):13149-57. PMID: 17804513; PMCID: PMC2169077.
    72. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks J, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007 Sep 1; 179(5):2815-23. PMID: 17709495.
      View in: PubMed
    73. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks J. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl). 2007 Oct; 85(10):1113-23. PMID: 17554518.
      View in: PubMed
    74. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks J. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug 24; 371(4):934-47. PMID: 17602702; PMCID: PMC4198021.
    75. Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks J, Poul MA. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul; 44(15):3777-88. PMID: 17498801; PMCID: PMC2739904.
    76. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks J. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007 Jan; 25(1):107-16. PMID: 17173035.
      View in: PubMed
    77. Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, Jackson PJ, Marks J. Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol. 2007 Feb; 189(3):818-32. PMID: 17114256; PMCID: PMC1797315.
    78. Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks J, Benz CC, Kirpotin DB. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006 Nov-Dec; 3(6):726-36. PMID: 17140260.
      View in: PubMed
    79. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks J. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol. 2007 Jan 5; 365(1):196-210. PMID: 17059824; PMCID: PMC1994578.
    80. Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks J. A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol. 2006; 7:24. PMID: 17014727; PMCID: PMC1633733.
    81. Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks J, Bertozzi CR, Bradbury AR. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics. 2006 Dec; 5(12):2350-63. PMID: 16971384.
      View in: PubMed
    82. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks J, Johnson EA, Stevens RC. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol. 2006 Sep 29; 362(4):733-42. PMID: 16938310.
      View in: PubMed
    83. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks J, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006 Jul 1; 66(13):6732-40. PMID: 16818648.
      View in: PubMed
    84. Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks J, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta. 2006 Jun 16; 570(2):137-43. PMID: 17723391.
      View in: PubMed
    85. Hayes ME, Drummond DC, Hong K, Park JW, Marks J, Kirpotin DB. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta. 2006 Apr; 1758(4):429-42. PMID: 16678786.
      View in: PubMed
    86. Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks J, Benz CC, Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther. 2006 Apr; 13(7):646-51. PMID: 16341056.
      View in: PubMed
    87. Adams GP, Tai MS, McCartney JE, Marks J, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006 Mar 1; 12(5):1599-605. PMID: 16533787.
      View in: PubMed
    88. Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks J. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2005 Dec; 20(6):603-13. PMID: 16398612.
      View in: PubMed
    89. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks J. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005 Sep; 73(9):5450-7. PMID: 16113261; PMCID: PMC1231122.
    90. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks J. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol. 2005 Aug 5; 351(1):158-69. PMID: 16002090.
      View in: PubMed
    91. Robinson MK, Doss M, Shaller C, Narayanan D, Marks J, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005 Feb 15; 65(4):1471-8. PMID: 15735035.
      View in: PubMed
    92. Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks J, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog. 2005 Jan-Feb; 21(1):221-32. PMID: 15903261.
      View in: PubMed
    93. Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks J, Park JW, Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2005 Jan-Feb; 21(1):205-20. PMID: 15903260.
      View in: PubMed
    94. Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks J, Cao C, Ugen K, Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol Dis. 2004 Oct; 17(1):114-21. PMID: 15350972.
      View in: PubMed
    95. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks J, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004 Sep 1; 64(17):6200-6. PMID: 15342405.
      View in: PubMed
    96. Marks J. Medical aspects of biologic toxins. Anesthesiol Clin North America. 2004 Sep; 22(3):509-32, vii. PMID: 15325716.
      View in: PubMed
    97. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks J, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004 Aug; 8(4):335-53. PMID: 15268628.
      View in: PubMed
    98. Bradbury AR, Marks J. Antibodies from phage antibody libraries. J Immunol Methods. 2004 Jul; 290(1-2):29-49. PMID: 15261570.
      View in: PubMed
    99. Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks J, Foster KA. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods. 2004 May; 288(1-2):55-60. PMID: 15183085.
      View in: PubMed
    100. Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks J, Feldhaus MJ. Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett. 2004 Apr 23; 564(1-2):24-34. PMID: 15094038.
      View in: PubMed
    101. Marks J. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord. 2004 Mar; 19 Suppl 8:S101-8. PMID: 15027061.
      View in: PubMed
    102. Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks J, Santoro C. Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods. 2004 Feb 1; 285(1):99-109. PMID: 14871539.
      View in: PubMed
    103. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks J. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10. PMID: 14744788.
      View in: PubMed
    104. Marks J. Antibody affinity maturation by chain shuffling. Methods Mol Biol. 2004; 248:327-43. PMID: 14970506.
      View in: PubMed
    105. Marks J, Bradbury A. PCR cloning of human immunoglobulin genes. Methods Mol Biol. 2004; 248:117-34. PMID: 14970493.
      View in: PubMed
    106. Marks J, Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol. 2004; 248:161-76. PMID: 14970495.
      View in: PubMed
    107. Marks J. Selection of internalizing antibodies for drug delivery. Methods Mol Biol. 2004; 248:201-8. PMID: 14970498.
      View in: PubMed
    108. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks J, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15; 63(12):3154-61. PMID: 12810643.
      View in: PubMed
    109. Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks J, Bradbury A. Predicting antigenic peptides suitable for the selection of phage antibodies. Hum Antibodies. 2003; 12(4):99-112. PMID: 15156098.
      View in: PubMed
    110. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks J, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol. 2002 Oct; 32(10):2773-82. PMID: 12355429.
      View in: PubMed
    111. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks J. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002 Aug 19; 1591(1-3):109-118. PMID: 12183061.
      View in: PubMed
    112. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks J. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11346-50. PMID: 12177434; PMCID: PMC123259.
    113. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks J. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol. 2002 Aug 2; 321(1):49-56. PMID: 12139932.
      View in: PubMed
    114. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks J, Fritz R, Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002 Jul 1; 186(1):64-73. PMID: 12089663.
      View in: PubMed
    115. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks J, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002 Apr; 8(4):1172-81. PMID: 11948130.
      View in: PubMed
    116. Visintin M, Settanni G, Maritan A, Graziosi S, Marks J, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002 Mar 15; 317(1):73-83. PMID: 11916379.
      View in: PubMed
    117. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks J. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002 Feb 22; 20(11-12):1640-8. PMID: 11858873.
      View in: PubMed
    118. Liu B, Huang L, Sihlbom C, Burlingame A, Marks J. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol. 2002 Feb 1; 315(5):1063-73. PMID: 11827476.
      View in: PubMed
    119. Lindquist EA, Marks J, Kleba BJ, Stephens RS. Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiology. 2002 Feb; 148(Pt 2):443-51. PMID: 11832508.
      View in: PubMed
    120. Mullaney BP, Pallavicini MG, Marks J. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun. 2001 Oct; 69(10):6511-4. PMID: 11553596; PMCID: PMC98787.
    121. Li X, Stuckert P, Bosch I, Marks J, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 2001 Aug; 8(8):555-65. PMID: 11571533.
      View in: PubMed
    122. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks J, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6; 74(1-3):95-113. PMID: 11489487.
      View in: PubMed
    123. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks J, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001 Jun 15; 61(12):4750-5. PMID: 11406547.
      View in: PubMed
    124. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks J, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001 May 15; 166(10):6112-7. PMID: 11342630.
      View in: PubMed
    125. Sheridan RE, Deshpande SS, Amersdorfer P, Marks J, Smith T. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. Toxicon. 2001 May; 39(5):651-7. PMID: 11072043.
      View in: PubMed
    126. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks J. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods. 2001 May 1; 251(1-2):123-35. PMID: 11292488.
      View in: PubMed
    127. Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks J. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2682-7. PMID: 11226299; PMCID: PMC30198.
    128. Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks J. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. 2001 Feb 1; 248(1-2):17-30. PMID: 11223066.
      View in: PubMed
    129. Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks J, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun. 2001 Jan 12; 280(1):274-9. PMID: 11162510.
      View in: PubMed
    130. Kallet RH, Siobal MS, Alonso JA, Warnecke EL, Katz JA, Marks J. Lung collapse during low tidal volume ventilation in acute respiratory distress syndrome. Respir Care. 2001 Jan; 46(1):49-52. PMID: 11175238.
      View in: PubMed
    131. Marshall KW, Marks J. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. J Immunother. 2001 Jan-Feb; 24(1):27-36. PMID: 11211146.
      View in: PubMed
    132. Nielsen UB, Adams GP, Weiner LM, Marks J. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15; 60(22):6434-40. PMID: 11103810.
      View in: PubMed
    133. Liu B, Marks J. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem. 2000 Nov 1; 286(1):119-28. PMID: 11038282.
      View in: PubMed
    134. Siegel RW, Allen B, Pavlik P, Marks J, Bradbury A. Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics. J Mol Biol. 2000 Sep 15; 302(2):285-93. PMID: 10970733.
      View in: PubMed
    135. Kallet RH, Katz JA, Pittet JF, Ghermey J, Siobal M, Alonso JA, Marks J. Measuring intra-esophageal pressure to assess transmural pulmonary arterial occlusion pressure in patients with acute lung injury: a case series and review. Respir Care. 2000 Sep; 45(9):1072-84. PMID: 10980099.
      View in: PubMed
    136. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks J. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep 1; 301(5):1149-61. PMID: 10966812.
      View in: PubMed
    137. Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks J, Weiner LM, Brechbiel MW. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 2000 May; 27(4):339-46. PMID: 10938467.
      View in: PubMed
    138. Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks J. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med. 2000 Apr; 161(4 Pt 1):1149-53. PMID: 10764304.
      View in: PubMed
    139. Katz JA, Kallet RH, Alonso JA, Marks J. Improved flow and pressure capabilities of the Datex-Ohmeda SmartVent anesthesia ventilator. J Clin Anesth. 2000 Feb; 12(1):40-7. PMID: 10773507.
      View in: PubMed
    140. Eberhard LW, Morabito DJ, Matthay MA, Mackersie RC, Campbell AR, Marks J, Alonso JA, Pittet JF. Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients. Crit Care Med. 2000 Jan; 28(1):125-31. PMID: 10667511.
      View in: PubMed
    141. Amersdorfer P, Marks J. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol. 2000; 145:219-40. PMID: 10820725.
      View in: PubMed
    142. Hughes-Jones NC, Bye JM, Gorick BD, Marks J, Ouwehand WH. Synthesis of Rh Fv phage-antibodies using VH and VL germline genes. Br J Haematol. 1999 Jun; 105(3):811-6. PMID: 10354152.
      View in: PubMed
    143. Cirino NM, Sblattero D, Allen D, Peterson SR, Marks J, Jackson PJ, Bradbury A, Lehnert BE. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun. 1999 Jun; 67(6):2957-63. PMID: 10338505; PMCID: PMC96606.
    144. McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks J, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999 May; 36(7):433-45. PMID: 10449096.
      View in: PubMed
    145. Poul MA, Marks J. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999 Apr 30; 288(2):203-11. PMID: 10329137.
      View in: PubMed
    146. Becerril B, Poul MA, Marks J. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999 Feb 16; 255(2):386-93. PMID: 10049718.
      View in: PubMed
    147. McCall AM, Amoroso AR, Sautès C, Marks J, Weiner LM. Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries. Immunotechnology. 1998 Jun; 4(1):71-87. PMID: 9661816.
      View in: PubMed
    148. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks J, Lindqvist E. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A. 1998 May 26; 95(11):6157-62. PMID: 9600934; PMCID: PMC27609.
    149. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks J. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May; 77(9):1405-12. PMID: 9652755; PMCID: PMC2150193.
    150. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks J. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998 Apr; 26(4):676-84. PMID: 9559604.
      View in: PubMed
    151. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks J, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998 Feb 1; 58(3):485-90. PMID: 9458094.
      View in: PubMed
    152. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks J. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997 Sep; 65(9):3743-52. PMID: 9284147; PMCID: PMC175534.
    153. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks J, Stevens RC. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun. 1997 May; 65(5):1626-30. PMID: 9125539; PMCID: PMC175186.
    154. Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks J, Lockwood CM, Ouwehand WH. Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol. 1997 Feb; 107(2):269-81. PMID: 9030863; PMCID: PMC1904567.
    155. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks J. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996 Nov 8; 263(4):551-67. PMID: 8918938.
      View in: PubMed
    156. Marks C, Marks J. Phage libraries--a new route to clinically useful antibodies. N Engl J Med. 1996 Sep 5; 335(10):730-3. PMID: 8703174.
      View in: PubMed
    157. Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks J. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene. 1996 Mar 9; 169(2):147-55. PMID: 8647439.
      View in: PubMed
    158. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks J. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol. 1996 Jan 12; 255(1):28-43. PMID: 8568873.
      View in: PubMed
    159. Schier R, Marks J. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas. 1996; 7(3):97-105. PMID: 9057057.
      View in: PubMed
    160. Finnern R, Bye JM, Dolman KM, Zhao MH, Short A, Marks J, Lockwood MC, Ouwehand WH. Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Clin Exp Immunol. 1995 Dec; 102(3):566-74. PMID: 8536374; PMCID: PMC1553387.
    161. Schier R, Marks J, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995 May; 1(1):73-81. PMID: 9373335.
      View in: PubMed
    162. Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, Marks J, Ouwehand WH. Characterization of human blood group scFv antibodies derived from a V gene phage-display library. Br J Haematol. 1994 Sep; 88(1):180-6. PMID: 7803241.
      View in: PubMed
    163. Figini M, Marks J, Winter G, Griffiths AD. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol. 1994 May 27; 239(1):68-78. PMID: 8196048.
      View in: PubMed
    164. Ouwehand WH, Bye JM, Gorick BD, Marks J, Timmers E, Griffin HM, Finnern R, Hughes-Jones N. The humoral immune response against blood group antigens at the molecular level. Vox Sang. 1994; 67 Suppl 3:7-12. PMID: 7975514.
      View in: PubMed
    165. Stackhouse RA, Marks J, Bainton CR. Performing fiberoptic endotracheal intubation: clinical aspects. Int Anesthesiol Clin. 1994; 32(4):57-73. PMID: 7875909.
      View in: PubMed
    166. Marks J. Fiberoptic-aided endobronchial intubation. Int Anesthesiol Clin. 1994; 32(4):75-84. PMID: 7875910.
      View in: PubMed
    167. Marks J, Bainton CR. Practical aspects of fiberoptic laryngobronchoscopy. Int Anesthesiol Clin. 1994; 32(4):31-46. PMID: 7875907.
      View in: PubMed
    168. Marks J, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, Thorpe SJ, Hughes-Jones NC, Winter G. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N Y). 1993 Oct; 11(10):1145-9. PMID: 7764095.
      View in: PubMed
    169. Griffiths AD, Malmqvist M, Marks J, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb; 12(2):725-34. PMID: 7679990; PMCID: PMC413258.
    170. Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes-Jones NC, Marks J. Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift. J Clin Invest. 1992 Dec; 90(6):2481-90. PMID: 1469099; PMCID: PMC443405.
    171. Hoogenboom HR, Marks J, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev. 1992 Dec; 130:41-68. PMID: 1286871.
      View in: PubMed
    172. Tomlinson IM, Walter G, Marks J, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol. 1992 Oct 5; 227(3):776-98. PMID: 1404388.
      View in: PubMed
    173. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks J, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol. 1992 Oct 5; 227(3):799-817. PMID: 1404389.
      View in: PubMed
    174. Marks J, Hoogenboom HR, Griffiths AD, Winter G. Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J Biol Chem. 1992 Aug 15; 267(23):16007-10. PMID: 1644788.
      View in: PubMed
    175. Marks J, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y). 1992 Jul; 10(7):779-83. PMID: 1368267.
      View in: PubMed
    176. Marks J, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991 Dec 5; 222(3):581-97. PMID: 1748994.
      View in: PubMed
    177. Hastings RH, Marks J. Airway management for trauma patients with potential cervical spine injuries. Anesth Analg. 1991 Oct; 73(4):471-82. PMID: 1897772.
      View in: PubMed
    178. Marks J, Tristem M, Karpas A, Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur J Immunol. 1991 Apr; 21(4):985-91. PMID: 2019291.
      View in: PubMed
    179. Songsivilai S, Bye JM, Marks J, Hughes-Jones NC. Cloning and sequencing of human lambda immunoglobulin genes by the polymerase chain reaction. Eur J Immunol. 1990 Dec; 20(12):2661-6. PMID: 2125272.
      View in: PubMed
    180. Biery DR, Marks J, Schapera A, Autry M, Schlobohm RM, Katz JA. Factors affecting perioperative pulmonary function in acute respiratory failure. Chest. 1990 Dec; 98(6):1455-62. PMID: 2123151.
      View in: PubMed
    181. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks J, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest. 1990 Aug; 86(2):474-80. PMID: 2384595; PMCID: PMC296749.
    182. Marks J, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan; 141(1):94-7. PMID: 2297191.
      View in: PubMed
    183. Marks J, Schapera A, Kraemer RW, Katz JA. Pressure and flow limitations of anesthesia ventilators. Anesthesiology. 1989 Sep; 71(3):403-8. PMID: 2672901.
      View in: PubMed
    184. Schapera A, Marks J, Minagi H, Goodman P, Katz JA. Perioperative pulmonary function in acute respiratory failure: effect of ventilator type and gas mixture. Anesthesiology. 1989 Sep; 71(3):396-402. PMID: 2774267.
      View in: PubMed
    185. Luce JM, Montgomery AB, Marks J, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988 Jul; 138(1):62-8. PMID: 3202402.
      View in: PubMed
    186. Hansen RM, Viquerat CE, Matthay MA, Wiener-Kronish JP, DeMarco T, Bahtia S, Marks J, Botvinick EH, Chatterjee K. Poor correlation between pulmonary arterial wedge pressure and left ventricular end-diastolic volume after coronary artery bypass graft surgery. Anesthesiology. 1986 Jun; 64(6):764-70. PMID: 3487261.
      View in: PubMed
    187. Katz JA, Marks J. Inspiratory work with and without continuous positive airway pressure in patients with acute respiratory failure. Anesthesiology. 1985 Dec; 63(6):598-607. PMID: 3904528.
      View in: PubMed
    188. Marks J, Luce JM, Lazar NM, Wu JN, Lipavsky A, Murray JF. Effect of increases in lung volume on clearance of aerosolized solute from human lungs. J Appl Physiol (1985). 1985 Oct; 59(4):1242-8. PMID: 3902778.
      View in: PubMed
    189. MARKS JD, ROESKY N, CARVER MJ. The inhibitory action of a phenothiazine derivative on the hexosemonophosphate dehydrogenases of adrenal cortex. Arch Biochem Biophys. 1961 Nov; 95:192-6. PMID: 14470052.
      View in: PubMed
    James's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP